| Biomarker ID | 978 |
| PMID | 22956952 |
| Year | 2012 |
| Biomarker | ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; |
| Biomarker Basis | Expression Based |
| Biomolecule | genes or ncRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated: AOX1-001, RSRC2-017, ABCC4-004, ALK-001, ATP1A1-002, NAMPT-006, RP11-627G23.1-004 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.0 |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Primary Vs Normal |
| Type of Biomarker | Diagnostic |
| Cohort | The human exon array files for 131 primary prostate cancer tumors, 29 normal adjacent and 19 metastatic tissue specimens were downloaded from GEO at GSE21034. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Microarray |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ACOT11-001, AOX1-001, C19orf46-002, C8orf84-001, COCH-202, CTA-55I10.1, 001, DMD-024, FGF10-002, FGFR2-008, FGFR2-016, GABRE-006, GNAL-001, GNAO1-002, HEATR8-006, ISL1-002, NR2F2-202, PCP4-004, PDE5A-005, PDZRN4-202, RSRC2-017, TGM4-001, TSPAN2-001, ABCC4-004, ALK-001, ATP1A1-002, NAMPT-006, NAMPT-007, RP11-627G23.1-004 |